Royal Bank Of Canada Increases Revolution Medicines (NASDAQ:RVMD) Price Target to $165.00

Revolution Medicines (NASDAQ:RVMD) had its target price raised by analysts at Royal Bank Of Canada from $162.00 to $165.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price would suggest a potential upside of 14.54% from the company’s current price.

Several other analysts have also recently issued reports on the stock. Wedbush boosted their price objective on shares of Revolution Medicines to $165.00 and gave the company an “outperform” rating in a research note on Thursday. UBS Group initiated coverage on shares of Revolution Medicines in a report on Friday, February 27th. They issued a “buy” rating on the stock. Evercore reiterated an “outperform” rating on shares of Revolution Medicines in a report on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a report on Tuesday, April 21st. Finally, Stifel Nicolaus reiterated a “buy” rating on shares of Revolution Medicines in a report on Monday, April 20th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $102.18.

Revolution Medicines Trading Down 4.6%

RVMD stock traded down $7.02 during midday trading on Thursday, hitting $144.06. The stock had a trading volume of 1,136,572 shares, compared to its average volume of 3,490,577. The firm has a market cap of $30.62 billion, a PE ratio of -24.32 and a beta of 1.41. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.14 and a quick ratio of 7.14. Revolution Medicines has a 12-month low of $34.00 and a 12-month high of $155.70. The company’s 50-day moving average price is $112.65 and its 200 day moving average price is $93.81.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same period in the previous year, the firm earned ($1.13) EPS. On average, equities research analysts predict that Revolution Medicines will post -7.42 earnings per share for the current fiscal year.

Insider Buying and Selling at Revolution Medicines

In related news, COO Margaret A. Horn sold 4,583 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $455,916.84. Following the sale, the chief operating officer owned 157,570 shares in the company, valued at $15,675,063.60. This represents a 2.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Lin Wei sold 2,073 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $206,222.04. Following the sale, the insider owned 101,366 shares in the company, valued at approximately $10,083,889.68. This trade represents a 2.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 184,592 shares of company stock valued at $24,499,532. Corporate insiders own 8.20% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

Several institutional investors and hedge funds have recently bought and sold shares of RVMD. Nextech Invest Ltd. raised its stake in Revolution Medicines by 20.7% during the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after acquiring an additional 1,304,347 shares during the period. Millennium Management LLC raised its stake in Revolution Medicines by 681.8% during the first quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock worth $5,529,000 after acquiring an additional 136,353 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Revolution Medicines by 14.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock worth $10,615,000 after acquiring an additional 37,345 shares during the period. Invesco Ltd. raised its stake in Revolution Medicines by 19.3% during the second quarter. Invesco Ltd. now owns 227,019 shares of the company’s stock worth $8,352,000 after acquiring an additional 36,760 shares during the period. Finally, Jump Financial LLC raised its stake in Revolution Medicines by 87.9% during the second quarter. Jump Financial LLC now owns 15,258 shares of the company’s stock worth $561,000 after acquiring an additional 7,137 shares during the period. Institutional investors and hedge funds own 94.34% of the company’s stock.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: New England Journal of Medicine published Phase 1/2 daraxonrasib data in pancreatic cancer, supporting the science behind the pivotal RASolute 302 trial and validating clinical benefit observed to date. NEJM Publication
• Positive Sentiment: Company reported that daraxonrasib produced an “unprecedented” survival benefit in the Phase 3 RASolute 302 trial, plans global regulatory submissions, and flagged ASCO plenary presentation of detailed data — all strong near-term regulatory and value catalysts. The company also strengthened its balance sheet with about $2.2B gross proceeds from financings. Q1 Results & Corporate Update
• Positive Sentiment: Analyst upgrades and higher targets: Piper Sandler raised its price target to $172 (overweight) and Wedbush raised its target to $165 (outperform), signaling institutional confidence in the longer-term upside tied to clinical progress. Piper Sandler Upgrade Wedbush Upgrade
• Neutral Sentiment: Reporting on side effects: Reuters notes the daraxonrasib data showed a high rate of mostly low-grade side effects — manageable for many patients but something regulators and clinicians will watch as the program moves toward approval. Reuters Side-Effects Report
• Neutral Sentiment: Earnings call transcript is available for details on R&D timing, regulatory plans and capital deployment; useful for investors who want management commentary that could clarify near-term milestones. Earnings Call Transcript
• Negative Sentiment: Q1 EPS missed expectations: RVMD reported ($2.29) EPS vs. consensus ($1.83) — a notable miss that likely pressured the stock today despite the upbeat clinical news. Earnings Release / Summary

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.